Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus UCERIS.
HYDROCORTISONE SODIUM PHOSPHATE vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium phosphate is a corticosteroid that binds to the glucocorticoid receptor, leading to regulation of gene transcription. It inhibits phospholipase A2, reducing pro-inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses immune cell migration and cytokine production.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
100-500 mg intravenously or intramuscularly every 2-6 hours as needed for acute conditions; typical dose 100 mg IV/IM every 8 hours.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 1.5–2 hours; in adrenal insufficiency, dose interval is 8 hours due to HPA axis suppression considerations.
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal: primarily as inactive metabolites, <1% unchanged; hepatic metabolism to tetrahydrocortisone and glucuronide conjugates; biliary/fecal excretion negligible.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category D/X
Category C
Corticosteroid
Corticosteroid